Eli Lilly Takes Legal Stand Against Unapproved Tirzepatide Sellers

Eli Lilly has filed lawsuits against three medical spas and online vendors for unlawfully selling products claiming to contain tirzepatide, the key ingredient in its weight-loss drug Zepbound. The legal actions target false advertising and potential consumer risks linked to misleading claims about the drugs' safety and efficacy.

Eli Lilly announced the filing of lawsuits against three medical spas and online vendors for reportedly selling unapproved products claiming to contain tirzepatide, a key ingredient in its popular weight-loss medicine Zepbound. Among those named in the suits are Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada.

The lawsuits represent the first legal action concerning copycat tirzepatide since the FDA removed the drug from its short supply list earlier this month. Eli Lilly emphasized that the filings were independent of the drug's availability status. The company accused these vendors of misleading advertisements and selling products without proper prescriptions.

Filed in federal and state courts across Indiana, Texas, and Washington, the lawsuits allege false advertising and dangerous consumer practices. Eli Lilly's spokesperson highlighted that these actions aim to safeguard public health while seeking to ban the sale of these imitation products and secure financial reparations for damages.

(With inputs from agencies.)